Client Novo Nordisk Expands AI-Based Cardiometabolic Drug Discovery Collaboration With Valo Health
January 10, 2025
January 10, 2025
BOSTON, Massachusetts, Jan. 10 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Novo Nordisk in expanding its collaboration with Valo Health in a deal worth up to $4.6 billion to discover and develop new treatments using artificial intelligence and real-world patient data to develop up to 20 treatments for obesity, type 2 diabetes and cardiovascular disease. The deal was announced on January 8.
In 2023, Ropes & Gray advised Novo Nor . . .
Ropes & Gray advised Novo Nordisk in expanding its collaboration with Valo Health in a deal worth up to $4.6 billion to discover and develop new treatments using artificial intelligence and real-world patient data to develop up to 20 treatments for obesity, type 2 diabetes and cardiovascular disease. The deal was announced on January 8.
In 2023, Ropes & Gray advised Novo Nor . . .